Overview

The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1

Status:
RECRUITING
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
Effects of Empagliflozin compared with placebo in cardiorenal syndrome type 1, evaluated by MAKE30.
Phase:
PHASE2
Details
Lead Sponsor:
Chulalongkorn University
Treatments:
empagliflozin